DOCSLIB.ORG

Mouse Alg13 Conditional Knockout Project (CRISPR/Cas9)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Mouse Alg13 Conditional Knockout Project (CRISPR/Cas9) https://www.alphaknockout.com Mouse Alg13 Conditional Knockout Project (CRISPR/Cas9) Objective: To create a Alg13 conditional knockout Mouse model (C57BL/6J) by CRISPR/Cas-mediated genome engineering. Strategy summary: The Alg13 gene (NCBI Reference Sequence: NM_026247 ; Ensembl: ENSMUSG00000041718 ) is located on Mouse chromosome X. 4 exons are identified, with the ATG start codon in exon 1 and the TAA stop codon in exon 4 (Transcript: ENSMUST00000070801). Exon 3~4 will be selected as conditional knockout region (cKO region). Deletion of this region should result in the loss of function of the Mouse Alg13 gene. To engineer the targeting vector, homologous arms and cKO region will be generated by PCR using BAC clone RP23-106O9 as template. Cas9, gRNA and targeting vector will be co-injected into fertilized eggs for cKO Mouse production. The pups will be genotyped by PCR followed by sequencing analysis. Note: Males hemizygous for a null allele exhibit environmentally induced seizures and increased susceptibility to pharmacologically induced seizures. Homozygous females for a different null allele show increased body fat and decrased lean body mass, decreased bone mineral density, decreased granulocyte numbers and increased leukocyte numbers. Exon 3~4 covers 50.71% of the coding region. Start codon is in exon 1, and stop codon is in exon 4. The size of intron 2 for 5'-loxP site insertion: 1950 bp. The size of effective cKO region: ~2389 bp. The cKO region does not have any other known gene. Page 1 of 8 https://www.alphaknockout.com Overview of the Targeting Strategy Wildtype allele 5' gRNA region gRNA region 3' 1 2 3 4 Targeting vector Targeted allele Constitutive KO allele (After Cre recombination) Legends Exon of mouse Alg13 Homology arm cKO region loxP site Page 2 of 8 https://www.alphaknockout.com Overview of the Dot Plot Window size: 10 bp Forward Reverse Complement Sequence 12 Note: The sequence of homologous arms and cKO region is aligned with itself to determine if there are tandem repeats. No significant tandem repeat is found in the dot plot matrix. So this region is suitable for PCR screening or sequencing analysis. Overview of the GC Content Distribution Window size: 300 bp Sequence 12 Summary: Full Length(8616bp) | A(25.94% 2235) | C(21.1% 1818) | T(32.16% 2771) | G(20.8% 1792) Note: The sequence of homologous arms and cKO region is analyzed to determine the GC content. Significant high GC-content regions are found. It may be difficult to construct this targeting vector. Page 3 of 8 https://www.alphaknockout.com BLAT Search Results (up) QUERY SCORE START END QSIZE IDENTITY CHROM STRAND START END SPAN ----------------------------------------------------------------------------------------------- browser details YourSeq 3000 1 3000 3000 100.0% chrX + 144318763 144321762 3000 browser details YourSeq 444 1786 2552 3000 90.8% chr10 - 62761682 63424311 662630 browser details YourSeq 397 2110 2556 3000 94.0% chr5 - 33075976 33076421 446 browser details YourSeq 394 2110 2552 3000 93.9% chr6 - 48523459 48523895 437 browser details YourSeq 393 2110 2552 3000 94.4% chr2 + 157521645 157522087 443 browser details YourSeq 393 2110 2552 3000 93.6% chr17 + 29136928 29137363 436 browser details YourSeq 391 2110 2546 3000 94.0% chr16 + 8922013 8922442 430 browser details YourSeq 389 2110 2552 3000 94.0% chr6 + 47815249 47815691 443 browser details YourSeq 384 2133 2923 3000 93.7% chr16 - 35919983 35920827 845 browser details YourSeq 383 2135 2846 3000 90.5% chr12 - 85662293 85662894 602 browser details YourSeq 382 2110 2929 3000 90.3% chr9 + 90221242 90221838 597 browser details YourSeq 382 2112 2552 3000 93.5% chr14 + 99365633 99366076 444 browser details YourSeq 381 2110 2552 3000 92.3% chr7 - 34175653 34176090 438 browser details YourSeq 379 2110 2552 3000 93.1% chr11 + 73225873 73226325 453 browser details YourSeq 377 2110 2526 3000 95.3% chr13 + 6662511 6662927 417 browser details YourSeq 377 2110 2526 3000 95.3% chr1 + 181241937 181242353 417 browser details YourSeq 376 2135 2552 3000 95.0% chr5 + 123255455 123255872 418 browser details YourSeq 370 2110 2526 3000 93.4% chr2 + 108874883 108875291 409 browser details YourSeq 366 2110 2552 3000 92.3% chr19 - 12524696 12525135 440 browser details YourSeq 365 1776 2544 3000 91.3% chr7 - 83705855 83706629 775 Note: The 3000 bp section upstream of Exon 3 is BLAT searched against the genome. No significant similarity is found. BLAT Search Results (down) QUERY SCORE START END QSIZE IDENTITY CHROM STRAND START END SPAN ----------------------------------------------------------------------------------------------- browser details YourSeq 3000 1 3000 3000 100.0% chrX + 144324129 144327128 3000 browser details YourSeq 615 1621 2468 3000 91.2% chr12 - 79415211 79416130 920 browser details YourSeq 611 1621 2449 3000 90.3% chr2 + 104904749 104905650 902 browser details YourSeq 606 1551 2438 3000 89.1% chr1 - 172843681 172844661 981 browser details YourSeq 605 1629 2471 3000 90.5% chrX + 71241767 71242676 910 browser details YourSeq 604 1636 2461 3000 91.4% chr12 - 39816517 39817414 898 browser details YourSeq 603 1621 2471 3000 89.9% chr6 - 148339838 148340772 935 browser details YourSeq 603 1647 2471 3000 89.2% chr9 + 59806865 59835699 28835 browser details YourSeq 602 1621 2449 3000 89.6% chr5 - 88359284 88360174 891 browser details YourSeq 602 1553 2471 3000 89.3% chr2 + 129642748 129643728 981 browser details YourSeq 602 1626 2471 3000 90.8% chr11 + 72773998 72774915 918 browser details YourSeq 596 1621 2471 3000 89.9% chr14 + 55375587 55376502 916 browser details YourSeq 595 1635 2471 3000 90.3% chr2 + 154064958 154065855 898 browser details YourSeq 594 1635 2471 3000 89.0% chr8 + 40689684 40690583 900 browser details YourSeq 594 1626 2448 3000 91.0% chr16 + 7730189 8145493 415305 browser details YourSeq 590 1553 2471 3000 89.6% chr9 - 7514746 7515740 995 browser details YourSeq 587 1634 2471 3000 90.3% chr8 - 5631553 5632453 901 browser details YourSeq 587 1635 2471 3000 89.1% chr4 + 122804985 122805883 899 browser details YourSeq 585 1668 2471 3000 88.3% chr18 + 6877717 6878583 867 browser details YourSeq 585 1658 2471 3000 90.0% chr14 + 99214239 99215107 869 Note: The 3000 bp section downstream of Exon 4 is BLAT searched against the genome. No significant similarity is found. Page 4 of 8 https://www.alphaknockout.com Gene and protein information: Alg13 asparagine-linked glycosylation 13 [ Mus musculus (house mouse) ] Gene ID: 67574, updated on 11-Sep-2019 Gene summary Official Symbol Alg13 provided by MGI Official Full Name asparagine-linked glycosylation 13 provided by MGI Primary source MGI:MGI:1914824 See related Ensembl:ENSMUSG00000041718 Gene type protein coding RefSeq status VALIDATED Organism Mus musculus Lineage Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae; Murinae; Mus; Mus Also known as MDS031; Glt28d1; 2810046O15Rik; 4833435D08Rik Expression Ubiquitous expression in testis adult (RPKM 4.3), limb E14.5 (RPKM 4.0) and 28 other tissues See more Orthologs human all Genomic context Location: X; X F2 See Alg13 in Genome Data Viewer Exon count: 28 Annotation release Status Assembly Chr Location 108 current GRCm38.p6 (GCF_000001635.26) X NC_000086.7 (144317966..144374450) Build 37.2 previous assembly MGSCv37 (GCF_000001635.18) X NC_000086.6 (140752509..140759740) Chromosome X - NC_000086.7 Page 5 of 8 https://www.alphaknockout.com Transcript information: This gene has 15 transcripts Gene: Alg13 ENSMUSG00000041718 Description asparagine-linked glycosylation 13 [Source:MGI Symbol;Acc:MGI:1914824] Gene Synonyms 2810046O15Rik, 4833435D08Rik, Glt28d1, MDS031 Location Chromosome X: 144,317,804-144,374,450 forward strand. GRCm38:CM001013.2 About this gene This gene has 15 transcripts (splice variants), 153 orthologues, 1 paralogue, is a member of 2 Ensembl protein families and is associated with 17 phenotypes. Transcripts Name Transcript ID bp Protein Translation ID Biotype CCDS UniProt Flags Alg13- ENSMUST00000070801.10 1802 165aa ENSMUSP00000068403.4 Protein coding CCDS30456 Q9D8C3 TSL:1 202 GENCODE basic APPRIS P1 Alg13- ENSMUST00000238864.1 4191 969aa ENSMUSP00000159009.1 Protein coding - - GENCODE 215 basic Alg13- ENSMUST00000123710.7 604 61aa ENSMUSP00000126052.2 Protein coding - E9Q161 TSL:1 203 GENCODE basic Alg13- ENSMUST00000149330.7 479 61aa ENSMUSP00000130514.2 Protein coding - E9Q161 TSL:2 207 GENCODE basic Alg13- ENSMUST00000154827.7 4168 155aa ENSMUSP00000131622.1 Nonsense mediated - E9PX10 TSL:1 210 decay Alg13- ENSMUST00000197316.4 3839 51aa ENSMUSP00000142956.1 Nonsense mediated - A0A0G2JEZ0 TSL:5 212 decay Alg13- ENSMUST00000198039.4 3307 48aa ENSMUSP00000143124.1 Nonsense mediated - A0A0G2JFD0 TSL:5 213 decay Alg13- ENSMUST00000145724.6 859 81aa ENSMUSP00000131340.3 Nonsense mediated - E9Q2P6 TSL:5 206 decay Alg13- ENSMUST00000197138.4 877 No - Retained intron - - TSL:5 211 protein Alg13- ENSMUST00000199040.1 719 No - Retained intron - - TSL:5 214 protein Alg13- ENSMUST00000149427.7 2996 No - lncRNA - - TSL:5 208 protein Alg13- ENSMUST00000132416.7 2608 No - lncRNA - - TSL:5 204 protein Alg13- ENSMUST00000149811.2 619 No - lncRNA - - TSL:5 209 protein Alg13- ENSMUST00000040338.8 508 No - lncRNA - - TSL:5 201 protein Alg13- ENSMUST00000144185.4 476 No - lncRNA - - TSL:5 205 protein Page 6 of 8 https://www.alphaknockout.com 76.65 kb Forward strand Genes (Comprehensive set... Alg13-215 >protein coding Alg13-202 >protein coding Alg13-201 >lncRNA Alg13-204 >lncRNA
Load more

Recommended publications
  • Congenital Disorders of Glycosylation from a Neurological Perspective
    brain sciences Review Congenital Disorders of Glycosylation from a Neurological Perspective Justyna Paprocka 1,* , Aleksandra Jezela-Stanek 2 , Anna Tylki-Szyma´nska 3 and Stephanie Grunewald 4 1 Department of Pediatric Neurology, Faculty of Medical Science in Katowice, Medical University of Silesia, 40-752 Katowice, Poland 2 Department of Genetics and Clinical Immunology, National Institute of Tuberculosis and Lung Diseases, 01-138 Warsaw, Poland; [email protected] 3 Department of Pediatrics, Nutrition and Metabolic Diseases, The Children’s Memorial Health Institute, W 04-730 Warsaw, Poland; [email protected] 4 NIHR Biomedical Research Center (BRC), Metabolic Unit, Great Ormond Street Hospital and Institute of Child Health, University College London, London SE1 9RT, UK; [email protected] * Correspondence: [email protected]; Tel.: +48-606-415-888 Abstract: Most plasma proteins, cell membrane proteins and other proteins are glycoproteins with sugar chains attached to the polypeptide-glycans. Glycosylation is the main element of the post- translational transformation of most human proteins. Since glycosylation processes are necessary for many different biological processes, patients present a diverse spectrum of phenotypes and severity of symptoms. The most frequently observed neurological symptoms in congenital disorders of glycosylation (CDG) are: epilepsy, intellectual disability, myopathies, neuropathies and stroke-like episodes. Epilepsy is seen in many CDG subtypes and particularly present in the case of mutations
    [Show full text]
  • De Novo Mutations in Epileptic Encephalopathies
    LETTER doi:10.1038/nature12439 De novo mutations in epileptic encephalopathies Epi4K Consortium* & Epilepsy Phenome/Genome Project* Epileptic encephalopathies are a devastating group of severe child- were found to be highly improbable (Table 1 and Fig. 1). We performed hood epilepsy disorders for which the cause is often unknown1.Here the same calculations on all of the genes with multiple de novo mutations we report a screen for de novo mutations in patients with two clas- observed in 610 control trios and found no genes with a significant excess sical epileptic encephalopathies: infantile spasms (n 5 149) and of de novo mutations (Supplementary Table 4). Although mutations in Lennox–Gastaut syndrome (n 5 115). We sequenced the exomes of GABRB3 have previously been reported in association with another type 264 probands, and their parents, and confirmed 329 de novo muta- of epilepsy15, and in vivo mouse studies suggest that GABRB3 haplo- tions. A likelihood analysis showed a significant excess of de novo insufficiency is one of the causes of epilepsy in Angelman’s syndrome16, mutations in the 4,000 genes that are the most intolerant to func- our observations implicate it, for the first time, as a single-gene cause of tional genetic variation in the human population (P 5 2.9 3 1023). epileptic encephalopathies and provide the strongest evidence to date for Among these are GABRB3,withde novo mutations in four patients, its association with any epilepsy. Likewise, ALG13, an X-linked gene and ALG13,withthesamede novo mutation in two patients; both encoding a subunit of the uridine diphosphate-N-acetylglucosamine genes show clear statistical evidence of association with epileptic transferase, was previously shown to carry a novel de novo mutation in encephalopathy.
    [Show full text]
  • Associated with Low Dehydrodolichol Diphosphate Synthase (DHDDS) Activity S
    Sabry et al. Orphanet Journal of Rare Diseases (2016) 11:84 DOI 10.1186/s13023-016-0468-1 RESEARCH Open Access A case of fatal Type I congenital disorders of glycosylation (CDG I) associated with low dehydrodolichol diphosphate synthase (DHDDS) activity S. Sabry1,2,3,4, S. Vuillaumier-Barrot1,2,5, E. Mintet1,2, M. Fasseu1,2, V. Valayannopoulos6, D. Héron7,8, N. Dorison8, C. Mignot7,8,9, N. Seta5,10, I. Chantret1,2, T. Dupré1,2,5 and S. E. H. Moore1,2* Abstract Background: Type I congenital disorders of glycosylation (CDG-I) are mostly complex multisystemic diseases associated with hypoglycosylated serum glycoproteins. A subgroup harbour mutations in genes necessary for the biosynthesis of the dolichol-linked oligosaccharide (DLO) precursor that is essential for protein N-glycosylation. Here, our objective was to identify the molecular origins of disease in such a CDG-Ix patient presenting with axial hypotonia, peripheral hypertonia, enlarged liver, micropenis, cryptorchidism and sensorineural deafness associated with hypo glycosylated serum glycoproteins. Results: Targeted sequencing of DNA revealed a splice site mutation in intron 5 and a non-sense mutation in exon 4 of the dehydrodolichol diphosphate synthase gene (DHDDS). Skin biopsy fibroblasts derived from the patient revealed ~20 % residual DHDDS mRNA, ~35 % residual DHDDS activity, reduced dolichol-phosphate, truncated DLO and N-glycans, and an increased ratio of [2-3H]mannose labeled glycoprotein to [2-3H]mannose labeled DLO. Predicted truncated DHDDS transcripts did not complement rer2-deficient yeast. SiRNA-mediated down-regulation of DHDDS in human hepatocellular carcinoma HepG2 cells largely mirrored the biochemical phenotype of cells from the patient.
    [Show full text]
  • Supplementary Table S1. List of Differentially Expressed
    Supplementary table S1. List of differentially expressed transcripts (FDR adjusted p‐value < 0.05 and −1.4 ≤ FC ≥1.4). 1 ID Symbol Entrez Gene Name Adj. p‐Value Log2 FC 214895_s_at ADAM10 ADAM metallopeptidase domain 10 3,11E‐05 −1,400 205997_at ADAM28 ADAM metallopeptidase domain 28 6,57E‐05 −1,400 220606_s_at ADPRM ADP‐ribose/CDP‐alcohol diphosphatase, manganese dependent 6,50E‐06 −1,430 217410_at AGRN agrin 2,34E‐10 1,420 212980_at AHSA2P activator of HSP90 ATPase homolog 2, pseudogene 6,44E‐06 −1,920 219672_at AHSP alpha hemoglobin stabilizing protein 7,27E‐05 2,330 aminoacyl tRNA synthetase complex interacting multifunctional 202541_at AIMP1 4,91E‐06 −1,830 protein 1 210269_s_at AKAP17A A‐kinase anchoring protein 17A 2,64E‐10 −1,560 211560_s_at ALAS2 5ʹ‐aminolevulinate synthase 2 4,28E‐06 3,560 212224_at ALDH1A1 aldehyde dehydrogenase 1 family member A1 8,93E‐04 −1,400 205583_s_at ALG13 ALG13 UDP‐N‐acetylglucosaminyltransferase subunit 9,50E‐07 −1,430 207206_s_at ALOX12 arachidonate 12‐lipoxygenase, 12S type 4,76E‐05 1,630 AMY1C (includes 208498_s_at amylase alpha 1C 3,83E‐05 −1,700 others) 201043_s_at ANP32A acidic nuclear phosphoprotein 32 family member A 5,61E‐09 −1,760 202888_s_at ANPEP alanyl aminopeptidase, membrane 7,40E‐04 −1,600 221013_s_at APOL2 apolipoprotein L2 6,57E‐11 1,600 219094_at ARMC8 armadillo repeat containing 8 3,47E‐08 −1,710 207798_s_at ATXN2L ataxin 2 like 2,16E‐07 −1,410 215990_s_at BCL6 BCL6 transcription repressor 1,74E‐07 −1,700 200776_s_at BZW1 basic leucine zipper and W2 domains 1 1,09E‐06 −1,570 222309_at
    [Show full text]
  • Characterization of X-Linked SNP Genotypic Variation in Globally Distributed Human Populations Genome Biology 2010, 11:R10
    Casto et al. Genome Biology 2010, 11:R10 http://genomebiology.com/2010/11/1/R10 RESEARCH Open Access CharacterizationResearch of X-Linked SNP genotypic variation in globally distributed human populations Amanda M Casto*1, Jun Z Li2, Devin Absher3, Richard Myers3, Sohini Ramachandran4 and Marcus W Feldman5 HumanAnhumanulation analysis structurepopulationsX-linked of X-linked variationand provides de geneticmographic insights variation patterns. into in pop- Abstract Background: The transmission pattern of the human X chromosome reduces its population size relative to the autosomes, subjects it to disproportionate influence by female demography, and leaves X-linked mutations exposed to selection in males. As a result, the analysis of X-linked genomic variation can provide insights into the influence of demography and selection on the human genome. Here we characterize the genomic variation represented by 16,297 X-linked SNPs genotyped in the CEPH human genome diversity project samples. Results: We found that X chromosomes tend to be more differentiated between human populations than autosomes, with several notable exceptions. Comparisons between genetically distant populations also showed an excess of X- linked SNPs with large allele frequency differences. Combining information about these SNPs with results from tests designed to detect selective sweeps, we identified two regions that were clear outliers from the rest of the X chromosome for haplotype structure and allele frequency distribution. We were also able to more precisely define the geographical extent of some previously described X-linked selective sweeps. Conclusions: The relationship between male and female demographic histories is likely to be complex as evidence supporting different conclusions can be found in the same dataset.
    [Show full text]
  • Targeted Next-Generation Sequencing in Patients with Suggestive X-Linked Intellectual Disability
    G C A T T A C G G C A T genes Article Targeted Next-Generation Sequencing in Patients with Suggestive X-Linked Intellectual Disability Nekane Ibarluzea 1,2 , Ana Belén de la Hoz 1,2, Olatz Villate 1,2,3, Isabel Llano 1,2,3 , Intzane Ocio 4, Itxaso Martí 5, Miriam Guitart 6, Elisabeth Gabau 6, Fernando Andrade 1,2, Blanca Gener 1,2,3 and María-Isabel Tejada 1,2,3,* 1 Biocruces Bizkaia Health Research Institute, 48903 Barakaldo, Spain; [email protected] (N.I.); [email protected] (A.B.d.l.H.); [email protected] (O.V.); [email protected] (I.L.); [email protected] (F.A.); [email protected] (B.G.) 2 Spanish Consortium for Research on Rare Diseases (CIBERER), 28029 Madrid, Spain 3 Genetics Service, Cruces University Hospital, Osakidetza Basque Health Service, 48903 Barakaldo, Spain 4 Department of Paediatric Neurology, Araba University Hospital, Osakidetza Basque Health Service, 01009 Gasteiz, Spain; [email protected] 5 Department of Paediatric Neurology, Donostia University Hospital, Osakidetza Basque Health Service, 20014 Donostia, Spain; [email protected] 6 Genetics Laboratory, Paediatric Unit, Parc Taulí Hospital Universitari, Institut d’Investigació i Innovació Parc Taulí I3PT, Universitat Autònoma de Barcelona, 08208 Sabadell, Spain; [email protected] (M.G.); [email protected] (E.G.) * Correspondence: [email protected] Received: 3 December 2019; Accepted: 30 December 2019; Published: 2 January 2020 Abstract: X-linked intellectual disability (XLID) is known to contribute up to 10% of intellectual disability (ID) in males and could explain the increased ratio of affected males observed in patients with ID.
    [Show full text]
  • Alg13/Alg14 UDP-Glcnac Transferase
    Heterodimeric Alg13/Alg14 UDP-GlcNAc transferase Introduction As one of the most frequent and common posttranslational modifications in eukaryotic cell, protein N-glycosylation begins with the multistep biosynthesis of an evolutionarily conserved lipid-linked oligosaccharide (LLO), which is extended by a series of membrane-associated Alg (asparagine-linked glycosylation) glycosyltransferases to produce Glc3Man9GlcNAc2-PP-dolichol (dol) in the endoplasmic reticulum (ER). As shown in figure 1, assembly of the first seven sugars in the LLO synthetic pathway takes place on the cytoplasmic face of the ER membrane, and is catalyzed by cytosolic glycosyltransferases that produce Man5GlcNAc2-PP-dol from the soluble nucleotide sugar substrates UDP-GlcNAc and GDP-man. This dol-linked intermediate then flips into the lumen of the ER where the next seven sugars are added from dol-linked sugar substrates to complete the assembly of the tetradecasaccharide on dolichol diphosphate. An UDP-N-acetylglucosamine transferase (accepted name: N-acetylglucosaminyldiphosphodolichol N-acetylglucosaminyltransferase) catalyzes the second step of LLO synthesis that adds N-acetylglucosamine (GlcNAc) to GlcNAc-pp-dol to produce GlcNAc2-PP-dol. Unlike any other Alg glycosyltransferases, this UDP-GlcNAc transferase is unique because it comprised of two subunits, Alg13 and Alg14 proteins (Figure 1). Alg13 and Alg14 homologous can be found in virtually all eukaryotic cells including man, mammals, insects, worms, plants and fungi. In yeast, both Alg13 and Alg14 subunits
    [Show full text]
  • Landscape of X Chromosome Inactivation Across Human Tissues Taru Tukiainen1,2, Alexandra-Chloé Villani2,3, Angela Yen2,4, Manuel A
    OPEN LETTER doi:10.1038/nature24265 Landscape of X chromosome inactivation across human tissues Taru Tukiainen1,2, Alexandra-Chloé Villani2,3, Angela Yen2,4, Manuel A. Rivas1,2,5, Jamie L. Marshall1,2, Rahul Satija2,6,7, Matt Aguirre1,2, Laura Gauthier1,2, Mark Fleharty2, Andrew Kirby1,2, Beryl B. Cummings1,2, Stephane E. Castel6,8, Konrad J. Karczewski1,2, François Aguet2, Andrea Byrnes1,2, GTEx Consortium†, Tuuli Lappalainen6,8, Aviv Regev2,9, Kristin G. Ardlie2, Nir Hacohen2,3 & Daniel G. MacArthur1,2 X chromosome inactivation (XCI) silences transcription from Given the limited accessibility of most human tissues, particularly one of the two X chromosomes in female mammalian cells to in large sample sizes, no global investigation into the impact of incom- balance expression dosage between XX females and XY males. plete XCI on X-chromosomal expression has been conducted in data- XCI is, however, incomplete in humans: up to one-third of sets spanning multiple tissue types. We used the Genotype-Tissue X-chromosomal genes are expressed from both the active and Expression (GTEx) project12,13 dataset (v6p release), which includes inactive X chromosomes (Xa and Xi, respectively) in female cells, high-coverage RNA-seq data from diverse human tissues, to investi- with the degree of ‘escape’ from inactivation varying between genes gate male–female differences in the expression of 681 X-chromosomal and individuals1,2. The extent to which XCI is shared between cells genes that encode proteins or long non-coding RNA in 29 adult tissues and tissues remains poorly characterized3,4, as does the degree to (Extended Data Table 1), hypothesizing that escape from XCI should which incomplete XCI manifests as detectable sex differences in gene typically result in higher female expression of these genes.
    [Show full text]
  • Predominant and Novel De Novo Variants in 29 Individuals with ALG13 Deficiency: Clinical
    Predominant and novel de novo variants in 29 individuals with ALG13 deficiency: Clinical description, biomarker status, biochemical analysis and treatment suggestions. Bobby G. Ng1, Erik A. Eklund1,2, Sergey A. Shiryaev1, Yin Y. Dong3, Mary-Alice Abbott4, Carla Asteggiano5, Michael J. Bamshad6,7, Eileen Barr8, Jonathan A. Bernstein9,10, Shabeed Chelakkadan11, John Christodoulou12, 13, Wendy K. Chung14, 15, Michael A. Ciliberto16, Janice Cousin17, Fiona Gardiner18, Suman Ghosh19, William D. Graf20, Stephanie Grunewald21, Katherine Hammond22, Natalie S. Hauser23, George E. Hoganson24, Kimberly M. Houck25, Jennefer N. Kohler9, 26, Eva Morava27, Austin A. Larson28, Pengfei Liu29, 30, Sujana Madathil16, Colleen McCormack9, 26, Naomi J.L. Meeks28, Rebecca Miller23, Kristin G. Monaghan31, Deborah A. Nickerson7, Timothy Blake Palculict31, Gabriela Magali Papazoglu32 , Beth A. Pletcher33, Ingrid E. Scheffer18,,34, Andrea Beatriz Schenone35, Rhonda E. Schnur31, Yue Si31, Leah J. Rowe28, Alvaro H. Serrano Russi36, 37, Rossana Sanchez Russo8, Farouq Thabet38, Allysa Tuite33, María Mercedes Villanueva35, Raymond Y. Wang39, 40, Richard I. Webster41, 42, Dorcas Wilson43, 44, Alice Zalan24, Undiagnosed Diseases Network, University of Washington Center for Mendelian Genomics (UW-CMG), Lynne A. Wolfe45, Jill A. Rosenfeld29, 30, Lindsay Rhodes31, Hudson H. Freeze1 This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/jimd.12290 This article is protected by copyright. All rights reserved. (1) Human Genetics Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA. (2) Lund University, Department of Clinical Sciences, Lund, Pediatrics, Lund, Sweden.
    [Show full text]
  • The Phenotypic Spectrum of X‐Linked, Infantile Onset ALG13‐Related
    Received: 11 June 2020 | Revised: 27 September 2020 | Accepted: 23 October 2020 DOI: 10.1111/epi.16761 FULL-LENGTH ORIGINAL RESEARCH The phenotypic spectrum of X-linked, infantile onset ALG13- related developmental and epileptic encephalopathy Alexandre N. Datta1 | Nadia Bahi-Buisson2 | Thierry Bienvenu3 | Sarah E. Buerki4 | Fiona Gardiner5 | J. Helen Cross6 | Bénédicte Heron7 | Anna Kaminska8 | Christian M. Korff9 | Anne Lepine10 | Gaetan Lesca11 | Amy McTague6 | Heather C. Mefford12 | Cyrill Mignot13 | Matthieu Milh9 | Amélie Piton14 | Ronit M. Pressler6,15 | Susanne Ruf16 | Lynette G. Sadleir17 | Anne de Saint Martin18 | Koen Van Gassen19 | Nienke E. Verbeek19 | Dorothée Ville20 | Nathalie Villeneuve10 | Pia Zacher21 | Ingrid E. Scheffer5,22 | Johannes R. Lemke23 1Pediatric Neurology and Developmental Medicine Department, University Children's Hospital, University of Basel, Basel, Switzerland 2Pediatric Neurology, Necker–Enfants Malades Children's Hospital, Paris and Institute IMAGINE, INSERM U1163, University of Paris, Paris, France 3Paris Institute of Psychiatry and Neuroscience, University of Paris, Paris, France 4Pediatric Neurology Department, University Children's Hospital Zürich, Switzerland 5Austin Health, University of Melbourne, Melbourne, Victoria, Australia 6Clinical Neuroscience, University College London–Great Ormond Street Institute of Child Health, London, UK 7Pediatric Neurology Department, Armand Trousseau–La Roche Guyon University Hospital, APHP and GRC No. 19, Sorbonne Universities, Paris, France 8Department of Clinical
    [Show full text]
  • The Transcriptomic Architecture of Mouse Sertoli Cell Clone Embryos Reveals Temporal–Spatial-Specific Reprogramming
    REPRODUCTIONRESEARCH The transcriptomic architecture of mouse Sertoli cell clone embryos reveals temporal–spatial-specific reprogramming Feng Cao, Atsushi Fukuda, Hiroshi Watanabe and Tomohiro Kono Department of Bioscience, Tokyo University of Agriculture, Setagaya-ku, Tokyo 156-8502, Japan Correspondence should be addressed to T Kono; Email: [email protected] Abstract Somatic cell nuclear transfer, a technique used to generate clone embryos by transferring the nucleus of a somatic cell into an enucleated oocyte, is an excellent approach to study the reprogramming of the nuclei of differentiated cells. Here, we conducted a transcriptomic study by performing microarray analysis on single Sertoli cell nuclear transfer (SeCNT) embryos throughout preimplantation development. The extensive data collected from the oocyte to the blastocyst stage helped to identify specific genes that were incorrectly reprogrammed at each stage, thereby providing a novel perspective for understanding reprogramming progression in SeCNT embryos. This attempt provided an opportunity to discuss the possibility that ectopic gene expression could be involved in the developmental failure of SeCNT embryos. Network analysis at each stage suggested that in total, 127 networks were involved in developmental and functional disorders in SeCNT embryos. Furthermore, chromosome mapping using our time-lapse expression data highlighted temporal–spatial changes of the abnormal expression, showing the characteristic distribution of the genes on each chromosome. Thus, the present study revealed that the preimplantation development of SeCNT embryos appears normal; however, the progression of incorrect reprogramming is concealed throughout development. Reproduction (2013) 145 277–288 Introduction into an enucleated oocyte (Gurdon et al. 1976), and Q-PCR studies have revealed that many genes were With progression of mammalian development, which abnormally expressed in SCNT embryos (Bortvin et al.
    [Show full text]
  • Genetic Characteristics of Non-Familial Epilepsy
    Genetic characteristics of non-familial epilepsy Kyung Wook Kang1, Wonkuk Kim2, Yong Won Cho3, Sang Kun Lee4, Ki-Young Jung4, Wonchul Shin5, Dong Wook Kim6, Won-Joo Kim7, Hyang Woon Lee8, Woojun Kim9, Keuntae Kim3, So-Hyun Lee10, Seok-Yong Choi10 and Myeong-Kyu Kim1 1 Department of Neurology, Chonnam National University Medical School, Gwangju, South Korea 2 Department of Applied Statistics, Chung-Ang University, Seoul, South Korea 3 Department of Neurology, Keimyung University Dongsan Medical Center, Daegu, South Korea 4 Department of Neurology, Seoul National University Hospital, Seoul, South Korea 5 Department of Neurology, Kyung Hee University Hospital at Gangdong, Seoul, South Korea 6 Department of Neurology, Konkuk University School of Medicine, Seoul, South Korea 7 Department of Neurology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea 8 Department of Neurology, Ewha Womans University School of Medicine and Ewha Medical Research Institute, Seoul, South Korea 9 Department of Neurology, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea 10 Department of Biomedical Science, Chonnam National University Medical School, Gwangju, South Korea ABSTRACT Background: Knowledge of the genetic etiology of epilepsy can provide essential prognostic information and influence decisions regarding treatment and management, leading us into the era of precision medicine. However, the genetic basis underlying epileptogenesis or epilepsy pharmacoresistance is not well-understood, particularly in non-familial epilepsies with heterogeneous phenotypes that last until or start in adulthood. Methods: We sought to determine the contribution of known epilepsy-associated Submitted 25 June 2019 genes (EAGs) to the causation of non-familial epilepsies with heterogeneous Accepted 22 November 2019 phenotypes and to the genetic basis underlying epilepsy pharmacoresistance.
    [Show full text]